Company intelligence / Profile preview

Bon Vivant

Lyon, Auvergne-Rhône-Alpes, Francebbvband.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Bon Vivant has developed precision-fermented animal-free milk proteins, including both whey and casein. The company has completed peer-reviewed life cycle assessments showing significant environmental benefits over conventional dairy. It achieved self-determined GRAS status for its recombinant whey protein in the US and expects to begin commercialization there by 2026. The company is currently focused on scaling production, regulatory approvals, and expanding B2B partnerships.

Modalities: Recombinant proteinPrecision fermentation protein
Industry: Non-Drug Biotech

Partnerships

Three undisclosed commercial partnerships secured in different markets as of late last year; further collaborations under discussion. Specific partners not named publicly yet.

Beyond the preview

Go deeper on Bon Vivant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bon Vivant.

Explore the full profile